|International Journal of Cardiology and Lipidology Research (Volume 4 Issue 2)|
|Statins and Malignancies in Cardiovascular Practice|
Wilhelm P. MistiaenDOI: http://dx.doi.org/10.15379/2410-2822.2017.04.02.01
Published: 06 October 2017
Statins have a proven efficacy in lowering of plasma cholesterol and reduction of atherosclerotic cardiovascular disease. They also have anti-inflammatory, pro-apoptotic and anti-angiogenic effects which can be derived from their biochemical activity. The cell cycle could also be arrested at several stages. However, an early concern was the possibility of increase in malignancy. The first reports were conflicting.
A search in Web of Science has been made with the terms “statins AND malignancy”, from 2012 to 2017.
Twenty of 119 manuscripts were considered as useful. Manuscripts dealing with in-vitro and animal experiments were excluded, as well as reviews and manuscripts not related to the topic. There was a variety of malignancies under scrutiny. Most series showed a favorable result on either reduction of incidence in malignancy or, if a malignancy was diagnosed and improvement in overall or cancer specific survival. Reduction in symptoms and improvement in inflammatory response after adjuvant chemo and radiotherapy were documented in a few reports.
|Statins, Malignancy, Survival, Atherosclerosis, Cholesterol.|